Advertisement

U.S. markets open in 1 hour 56 minutes

S&P Futures
4,275.75
-32.00(-0.74%)
Dow Futures
33,932.00
-186.00(-0.55%)
Nasdaq Futures
13,537.25
-121.00(-0.89%)
Russell 2000 Futures
2,008.10
-15.20(-0.75%)
Crude Oil
86.44
-0.09(-0.10%)
Gold
1,782.10
-7.60(-0.42%)

Advertisement

Beam Therapeutics Inc. (BEAM)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

Add to watchlist

Visitors trend2W10W9M

63.56

-6.75

(-9.60%)

At close: 04:00PM EDT

63.56

0.00

(0.00%)

Pre-Market:

07:00AM EDT

Advertisement

Full screen

Trade prices are not sourced from all markets

Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies

Chart Events

Bullishpattern detected

Triple Moving Average Crossover

View all chart patterns

Performance Outlook

Previous Close	70.31
Open	69.30
Bid	62.50 x 800
Ask	65.00 x 2900
Day's Range	62.77 - 69.97
52 Week Range	27.77 - 116.91
Volume	1,442,899
Avg. Volume	1,320,350

Market Cap	4.472B
Beta (5Y Monthly)	1.76
PE Ratio (TTM)	N/A
EPS (TTM)	N/A
Earnings Date	N/A
Forward Dividend & Yield	N/A (N/A)
Ex-Dividend Date	N/A
1y Target Est	N/A

Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.

Fair Value

XX.XX

Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for BEAM

View details

Research that delivers an independent perspective, consistent methodology and actionable insight

Related Research

Beam Therapeutics Inc.
Analyst Report: CRISPR Therapeutics AGCRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR’s most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Rating
Fair Value
Economic Moat
7 days agoMorningstar